Drug intelligence / Profile preview

Sativol

Development stage: Unknown
Lead developer: Satispharm
Modality: Small Molecules
Administration: Oral

Overview

Sativol is a GMP-produced cannabidiol (CBD) capsule developed by Satipharm, a Swiss-based subsidiary of MMJ Bioscience, in collaboration with Ai Fame GmbH and Gelpell AG. It is intended as a cannabinoid-based health and wellness product for the E.U. market. Cannabidiol is a non-psychoactive compound from Cannabis sativa with a complex and multi-targeted mechanism of action, influencing inflammation, pain, neuronal excitability, and other physiological processes.

Brand names: Sativol

Targets

FAAH

Beyond the preview

Go deeper on Sativol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sativol.

Explore the full profile